KWM
PRME icon

Kingsview Wealth Management’s Prime Medicine PRME Stock Holding History

Kingsview Wealth Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Buy
35,000
+20,000
+133% +$76.1K ﹤0.01% 1287
2025
Q4 		$52K Sell
15,000
-9,750
-39% -$43.4K ﹤0.01% 1223
2025
Q3 		$137K Sell
24,750
-250
-1% -$1.02K ﹤0.01% 1165
2025
Q2 		$61.8K Buy
+25,000
New +$38.5K ﹤0.01% 1149

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Kingsview Wealth Management's PRME Position: Q1 2026 in Review

Kingsview Wealth Management increased its Prime Medicine (PRME) stake by 133% in Q1 2026, buying an estimated $76.1K and bringing the position to 35,000 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #1287.

Kingsview Wealth Management first reported a position in PRME in Q2 2025 and has held it in 4 quarters since. The position peaked at $137K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Kingsview Wealth Management held 35,000 shares of Prime Medicine worth $122K as of Q1 2026.
  • Kingsview Wealth Management bought 20,000 Prime Medicine shares in Q1 2026, an estimated $76.1K.
  • Prime Medicine made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q1 2026, its #1287 holding.
  • Kingsview Wealth Management first reported a position in Prime Medicine in Q2 2025 and has held it in 4 quarters since.
  • Kingsview Wealth Management's Prime Medicine position peaked at $137K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.